Ascites Clinical Trial
Official title:
Spontaani Bakterielli Peritoniitti: Esiintyvyys, riskitekijät ja Vaikutus Ennusteeseen
Spontaneous bacterial peritonitis (SBP) is a severe complication of ascites in cirrhotic patients. Under clinical experience, this condition seems to be more uncommon in Finland. The aim of this study was to measure the incidence of SBP in consecutive patients with ascites requiring hospitalization in a Finnish University Hospital.
Spontaneous bacterial peritonitis (SBP) is a complication of liver cirrhosis with high mortality and low survival rates. The incidence of SBP is reported to range from 11-35% in patients with ascites requiring hospitalization. Under clinical experience, the incidence of SBP in Finland seems to be lower than reported elsewhere. Alcohol is the dominant etiologic factor of liver cirrhosis in Finland (90%), which might be a factor affecting the incidence of SBP. The aim of this study is to measure the incidence of SBP in Finland. We included consecutive patients who underwent diagnostic paracentesis for ascites in Tampere University Hospital during 2/1994 - 12/1998 and 1/2005 - 3/2007. Spontaneous bacterial peritonitis was diagnosed when the ascitic fluid contained over 250 polymorphonuclear cells / mm^3 regardless of culture and with no evidence of intra-abdominal source of infection e.g. an abscess or a perforation. ;
Observational Model: Defined Population, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02891642 -
Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
|
||
| Recruiting |
NCT00239096 -
Prevention of Decompensation in Liver Cirrhosis
|
Phase 4 | |
| Active, not recruiting |
NCT03973866 -
Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)
|
N/A | |
| Terminated |
NCT01455246 -
Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
|
Phase 2/Phase 3 | |
| Completed |
NCT01349348 -
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
|
Phase 3 | |
| Completed |
NCT01578226 -
Procalcitonin in Cirrhotic Patients at High Risk for Sepsis
|
N/A | |
| Terminated |
NCT00548366 -
Sodium Restriction in the Management of Cirrhotic Ascites
|
Phase 4 | |
| Recruiting |
NCT05025878 -
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
|
||
| Completed |
NCT03327688 -
Point-of-care Ultrasound in Finland
|
N/A | |
| Not yet recruiting |
NCT04550091 -
Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
|
||
| Not yet recruiting |
NCT01716611 -
Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
|
Phase 4 | |
| Completed |
NCT01769040 -
Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
|
Phase 4 | |
| Recruiting |
NCT05700708 -
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
|
||
| Recruiting |
NCT05511766 -
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
|
Phase 2/Phase 3 | |
| Completed |
NCT05013502 -
Empagliflozin in Diuretic Refractory Ascites
|
Phase 1 | |
| Not yet recruiting |
NCT06436807 -
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
|
||
| Completed |
NCT03263598 -
Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites
|
||
| Completed |
NCT00907673 -
The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure
|
N/A | |
| Terminated |
NCT00796861 -
Trial of Sunitinib for Refractory Malignant Ascites
|
Phase 2 | |
| Suspended |
NCT00511394 -
Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis
|
N/A |